Basilea Pharmaceutica has recorded another CHF2.2m in milestone payments triggered by both commercial anti-infective products, Cresemba and Zevtera, hitting sales thresholds in specific geographies in 2024. This includes milestone payments from Canada (by partner AVIR Pharma) and the MENA region (from Hikma Pharmaceuticals) for Cresemba and Europe (from Advanz pharma) for Zevtera. This adds to an already strong year for Basilea, which has seen the company book c CHF40m in milestone payments during the year.
In December, Innoviva Specialty Therapeutics was announced as the US commercial partner for Zevtera and we expect the market launch of the antibiotic as a key upcoming catalyst. Basilea is expected to report full-year FY24 results on 18 February 2025.
Industrials | Comment
TMT | Comment
Industrials | Comment
Industrials | Comment